These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 7520515

  • 1. [Granulocyte function of patients on anti-cancer chemotherapy].
    Okada H, Miyazaki J, Kamidono S.
    Nihon Hinyokika Gakkai Zasshi; 1994 Jun; 85(6):958-63. PubMed ID: 7520515
    [Abstract] [Full Text] [Related]

  • 2. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S, Kubota Y, Shuin T, Hosaka M, Miura T, Kondoh I.
    Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
    [Abstract] [Full Text] [Related]

  • 3. [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer].
    Okaneya T, Tsuruta T, Niwakawa M, Kawakami M, Kobayashi S, Ogawa A.
    Nihon Hinyokika Gakkai Zasshi; 1993 Apr; 84(4):680-5. PubMed ID: 7684099
    [Abstract] [Full Text] [Related]

  • 4. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
    Aso Y, Akaza H.
    J Urol; 1992 Apr; 147(4):1060-4. PubMed ID: 1372661
    [Abstract] [Full Text] [Related]

  • 5. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 6. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 7. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M, Kadena H, Ueda M, Usui T.
    Cancer Chemother Pharmacol; 1994 Sep; 35 Suppl():S1-4. PubMed ID: 7527732
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ, Iscoe N, Tannock IF.
    J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
    [Abstract] [Full Text] [Related]

  • 9. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA, Scher HI.
    Cancer; 1992 Dec 01; 70(11):2699-702. PubMed ID: 1384952
    [Abstract] [Full Text] [Related]

  • 10. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L.
    N Engl J Med; 1988 Jun 02; 318(22):1414-22. PubMed ID: 2452983
    [Abstract] [Full Text] [Related]

  • 11. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun 02; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 12. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN, de Mulder PH, van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR.
    Ann Oncol; 1993 May 02; 4(5):403-7. PubMed ID: 8353075
    [Abstract] [Full Text] [Related]

  • 13. [Effects of recombinant human granulocyte colony-stimulating factor on superoxide production by neutrophil in cancer patients receiving chemotherapy].
    Yoshida M, Oshi M, Aso Y, Yanagisawa R, Kishi H, Ishida Y.
    Nihon Hinyokika Gakkai Zasshi; 1993 Jul 02; 84(7):1262-8. PubMed ID: 7689123
    [Abstract] [Full Text] [Related]

  • 14. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 02; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 15. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y.
    J Clin Oncol; 1993 Mar 02; 11(3):408-14. PubMed ID: 7680373
    [Abstract] [Full Text] [Related]

  • 16. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
    Obata K, Kobayashi H, Takaba H, Yokoi K, Hikosaka A.
    Hinyokika Kiyo; 1994 Oct 02; 40(10):939-44. PubMed ID: 7527613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Solé LA, Baselga J.
    Cancer; 1997 Nov 15; 80(10):1966-72. PubMed ID: 9366300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.